CompletedPhase 1ACTRN12605000782639
A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers
Sponsor
Epitan Limited
Enrollment
6 participants
Start Date
Jan 10, 2006
Study Type
Interventional
Conditions
Summary
To determine how a new implant design of EPT1647 works in the body and to review any side effects that may occur.
Eligibility
Sex: MalesMin Age: 18 YearssMax Age: 45 Yearss
Inclusion Criteria1
- Healthy caucasian * No history of Melanoma includinjg in a first degree relative* No significant medical history or disorder* Take precautions to prevent pregnancy during and upto 3 months after study.* No history of drug or alcohol abuse.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EPT1647 is a derivative of MSH which has been shown to increase eumelanin levels in humans. This study will evaluate the safety and pharmacokinetic profiles of a new formulation of EPT1647 over 30 day
EPT1647 is a derivative of MSH which has been shown to increase eumelanin levels in humans. This study will evaluate the safety and pharmacokinetic profiles of a new formulation of EPT1647 over 30 days.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000782639
Related Trials
A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults
NCT075786361 location
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019
NCT074797451 location
The effect of Glycine Betaine on fasting and Post methionine load homocysteine concentrations in healthy volunteers.
ACTRN126050004346951 location